Multiple Sclerosis Drugs - France

France

The projected revenue for the Multiple Sclerosis Drugs market in France is estimated to reach €0.48bn by 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 0.41%, leading to a market volume of €0.49bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to €10,910.00m in 2024.
France's robust healthcare system and commitment to research make it a leading market for innovative multiple sclerosis drugs.

Key regions: France, India, United Kingdom, South Korea, Japan

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Multiple Sclerosis Drugs market in France has seen significant growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in France have shown a preference for disease-modifying therapies that can slow down the progression of the disease. They also prefer treatments that can improve their quality of life by reducing the frequency and severity of relapses. Patients in France are also increasingly interested in treatments that have fewer side effects and are more convenient to administer.

Trends in the market: The Multiple Sclerosis Drugs market in France has witnessed a shift towards newer and more advanced treatments. There has been a significant increase in the use of oral therapies, which are more convenient for patients and have fewer side effects compared to injectable therapies. In addition, the market has seen the introduction of several new disease-modifying therapies that have shown promising results in clinical trials. These therapies target specific mechanisms of the disease and have the potential to be more effective than existing treatments.

Local special circumstances: France has a well-established healthcare system that provides universal coverage to its citizens. This has led to a high demand for Multiple Sclerosis Drugs in the country. In addition, France has a large population of patients suffering from Multiple Sclerosis, which has contributed to the growth of the market. The French government has also taken steps to promote the use of newer and more advanced treatments by providing subsidies for innovative therapies.

Underlying macroeconomic factors: The growth of the Multiple Sclerosis Drugs market in France can be attributed to several underlying macroeconomic factors. These include the increasing prevalence of Multiple Sclerosis in the country, the growing awareness of the disease among patients and healthcare professionals, and the availability of advanced treatments. In addition, the French government's support for innovative therapies has encouraged pharmaceutical companies to invest in research and development, which has led to the introduction of newer and more effective treatments in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.